Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Currently Reading
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer

As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.


As the technology improves, we’re going to see liquid biopsies used in multiple different cancers, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Transcript

Liquid biopsies have shown promise in lung cancer and most recently in breast cancer. Do you think use of these biopsies will become more prevalent in the future?

I think liquid biopsies are going to be very important in the precision oncology world of tomorrow. I just returned from AACR [American Association for Cancer Research], and there were many presentations in 2019 about liquid biopsies. So, the technology is developing very quickly. The idea that tumors shed both cells and circulating tumor DNA, as well as other some subcellular molecules like microRNA and proteins into the blood stream, means that really the blood is a rich source of understanding the dynamics of how tumors grow and shrink. So, as the technology improves, and as the studies are done to show concordance against tissue biopsies, we’re going to see liquid biopsies used in multiple different directions.

Right now, they’re good for when you don’t have a tissue biopsy available or there’s a limited sample or not enough to do next-generation sequencing, for example, we can get those results from a liquid biopsy. I think in metastatic cancer, it’s going to be very useful to monitor patients to see what happens, because tumors unfortunately change over time. They can find resistance mechanisms to get around some of the medicines we use. And of course, there’s a lot of interest in early diagnosis using liquid biopsies, and many companies are working on tests that can be used broadly to screen patients for cancer when they have no symptoms. So, we’re very excited about the entire spectrum of liquid biopsies. There’s a lot of work that needs to be done. There’s a lot of clinical trials to show the clinical utility, but the validation—technical validation and the clinical validation—has already been largely done.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up